Amneal Pharmaceuticals (AMRX) Scheduled to Post Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) will be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.570-0.630 EPS.Persons interested in participating in the company's earnings conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The company had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Stock Up 0.2 %

AMRX traded up $0.02 during trading on Friday, hitting $8.49. 922,984 shares of the company's stock were exchanged, compared to its average volume of 1,401,743. Amneal Pharmaceuticals has a fifty-two week low of $3.91 and a fifty-two week high of $8.95. The stock has a market cap of $2.63 billion, a P/E ratio of -13.66 and a beta of 1.18. The business's 50 day moving average is $8.53 and its two-hundred day moving average is $7.41.

Wall Street Analysts Forecast Growth

AMRX has been the topic of several recent research reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, October 2nd. Finally, Barclays upped their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $9.40.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.